AdAPT-001: An immune checkpoint sensitizer that aims to convert tumors from inoperable to operable.
The antitumor responses seen with AdAPT-001 + checkpoint inhibitors in checkpoint inhibitor-resistant tumors indicate a mechanism of synergy in ongoing late stage clinical trials.
EpicentRx’s CEO, Dr. Tony Reid, is the inventor of the AdAPT Immunotherapy Platform and a pioneer in the field of Immuno-Oncology.
AdAPT™ Platform Manufacturability
The manufacture of pharmaceutical grade gene therapy vectors at the scale needed for large phase trials and commercialization has historically been a rate-limiting bottleneck with prohibitively long lead times. Thanks to the unique expertise of dedicated EpicentRx personnel, the company has developed a robust, high-titer process suitable for clinical studies all within its own GMP facility.
